Syqe Medical

Syqe is an Israeli healthtech company that developed the Syqe Inhaler, a medical-grade device designed to deliver precise, consistent doses of medical cannabis via inhalation. Inconsistent dosing has been a core barrier to clinical adoption of inhaled cannabis, and Syqe's device is engineered to control vaporization temperature and active-ingredient delivery with clinical accuracy. Philip Morris International (PMI) invested in Syqe as part of its strategic diversification beyond conventional cigarettes, a partnership that received notable press coverage.

The Syqe Inhaler targets clinical and medical use cases, not the recreational consumer market. The device is positioned for patients receiving medical cannabis under clinical supervision, where dosing consistency is a medical requirement rather than a preference. The scientific moat is the precise control over the vaporization process that produces a measurable, repeatable dose.

Detailed public information on headcount, specific funding rounds, executive leadership, and current commercial status is limited.